Table 2 The clinical and tumor characteristics between patients with bone metastasis and patients without bone metastasis in development cohort
Characteristic | Patients without BM (Nā=ā39,029) | Patients with BM (Nā=ā208) | P value |
|---|---|---|---|
Age at diagnosis (years) | Ā | Ā | 0.004 |
āā<ā60 | 13,582 (34.8%) | 92 (44.2%) | Ā |
āāā„ā60 | 25,447 (65.2%) | 116 (55.8%) | Ā |
Sex | Ā | Ā | 0.083 |
āFemale | 18,671 (47.8%) | 87 (41.8%) | Ā |
āMale | 20,358 (52.2%) | 121 (58.2%) | Ā |
Tumor location | Ā | Ā | 0.002 |
āColon | 31,776 (81.4%) | 152 (73.1%) | Ā |
āRectum | 7,253 (18.6%) | 56 (26.9%) | Ā |
Grade | Ā | Ā | 0.000 |
āWell-Moderate differentiation | 31,361 (80.4%) | 134 (64.4%) | Ā |
āPoorly-Undifferentiation | 7,668 (19.6%) | 74 (35.6%) | Ā |
Histological type | Ā | Ā | 0.000 |
āAdenocarcinoma | 35,131 (90.0%) | 172 (82.6%) | Ā |
āMucinous adenocarcinoma | 3,122 (8.0%) | 18 (8.7%) | Ā |
āSignet-ring cell carcinoma | 776 (2.0%) | 18 (8.7%) | Ā |
CEA | Ā | Ā | 0.000 |
ā(ā) | 22,016 (56.4%) | 39 (18.7%) | Ā |
ā(+) | 17,013 (43.6%) | 169 (81.3%) | Ā |
Tumor size (cm) | Ā | Ā | 0.000 |
āā<ā2 | 3,519 (9.0%) | 10 (4.8%) | Ā |
ā2ā5 | 18,211 (46.7%) | 76 (36.5%) | Ā |
āāā„ā5 | 17,299 (44.3%) | 122 (58.7%) | Ā |
AJCC T stage | Ā | Ā | 0.000 |
āT1/T2 | 9,346 (23.9%) | 27 (13.0%) | Ā |
āT3/T4 | 29,683 (76.1%) | 181 (87.0%) | Ā |
AJCC N stage | Ā | Ā | 0.000 |
āN0 | 20,560 (52.7%) | 48 (23.1%) | Ā |
āN1/N2 | 18,469 (47.3%) | 160 (76.9%) | Ā |
Brain metastasis | Ā | Ā | 0.000 |
āNo | 38,984 (99.9%) | 199 (95.7%) | Ā |
āYes | 45 (0.1%) | 9 (4.3%) | Ā |
Liver metastasis | Ā | Ā | 0.000 |
āNo | 34,633 (88.7%) | 62 (29.8%) | Ā |
āYes | 4,396 (11.3%) | 146 (70.2%) | Ā |
Lung metastasis | Ā | Ā | 0.000 |
āNo | 38,000 (97.4%) | 128 (61.5%) | Ā |
āYes | 1,029 (2.6%) | 80 (38.5%) | Ā |